These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8815009)

  • 1. Recombinant antibody fusion proteins for cancer immunotherapy.
    Reisfeld RA; Gillies SD
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
    [No Abstract]   [Full Text] [Related]  

  • 2. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.
    Sabzevari H; Gillies SD; Mueller BM; Pancook JD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9626-30. PubMed ID: 7937818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
    Reisfeld RA; Gillies SD
    J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice.
    Qi Y; Moyana T; Bresalier R; Xiang J
    Gastroenterology; 1995 Dec; 109(6):1950-7. PubMed ID: 7498661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-cytokine fusion proteins.
    Kontermann RE
    Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
    Melief CJ
    Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
    Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
    Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Our experience with lymphocytes activated against cancer: CTL cells].
    Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
    G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 11. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
    Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-directed, effector cell-mediated tumor destruction.
    Sondel PM; Hank JA
    Hematol Oncol Clin North Am; 2001 Aug; 15(4):703-21. PubMed ID: 11676280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in cancer immunotherapy.
    Ockert D; Schmitz M; Hampl M; Rieber EP
    Immunol Today; 1999 Feb; 20(2):63-5. PubMed ID: 10098323
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
    Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
    Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy for cancer.
    Rosenberg SA
    Sci Am; 1990 May; 262(5):62-9. PubMed ID: 2333496
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current aspects and trends in immunotherapy of cancer].
    Boniver J; Schaaf-Lafontaine N; Moutschen M; Longrée L; Lovens-Degraef D; Fassotte MF; Reginster MA; Simonet-Martin MT; Baudrihaye M
    Rev Med Liege; 1990 Feb; 45(2):41-8. PubMed ID: 2138351
    [No Abstract]   [Full Text] [Related]  

  • 19. Circumvention of tumor cell escape following specific immunotherapy.
    Frost P; Bonavida B
    Cancer Biother Radiopharm; 2000 Apr; 15(2):141-52. PubMed ID: 10803319
    [No Abstract]   [Full Text] [Related]  

  • 20. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.